Review
. 2015 Oct; 17 Suppl 7:vii32-vii40.
doi: 10.1093/neuonc/nov178.

Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy

David A Reardon 1 Mark R Gilbert 1 Wolfgang Wick 1 Linda Liau 1 
Affiliations
  • PMID: 26516225
  •     127 References
  •     9 citations

Abstract

A successful therapeutic paradigm established historically in oncology involves combining agents with potentially complementary mechanisms of antitumor activity into rationally designed regimens. For example, cocktails of cytotoxic agents, which were carefully designed based on mechanisms of action, dose, and scheduling considerations, have led to dramatic improvements in survival including cures for childhood leukemia, Hodgkin's lymphoma, and several other complex cancers. Outcome for glioblastoma, the most common primary malignant CNS cancer, has been more modest, but nonetheless our current standard of care derives from confirmation that combination therapy surpasses single modality therapy. Immunotherapy has recently come of age for medical oncology with exciting therapeutic benefits achieved by several types of agents including vaccines, adoptive T cells, and immune checkpoint inhibitors against several types of cancers. Nonetheless, most benefits are relatively short, while others are durable but are limited to a minority of treated patients. Critical factors limiting efficacy of immunotherapeutics include insufficient immunogenicity and/or inadequate ability to overcome immunosuppressive factors exploited by tumors. The paradigm of rationally designed combinatorial regimens, originally established by cytotoxic therapy for oncology, may also prove relevant for immunotherapy. Realization of the true therapeutic potential of immunotherapy for medical oncology and neuro-oncology patients may require development of combinatorial regimens that optimize immunogenicity and target tumor adaptive immunosuppressive factors.

Keywords: glioblastoma; immune checkpoint; immunotherapy; programmed-death 1; vaccine.

Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.
Anna Sophie Berghoff, Barbara Kiesel, +14 authors, Wolfgang Wick.
Neuro Oncol, 2014 Oct 31; 17(8). PMID: 25355681    Free PMC article.
Highly Cited.
Mechanisms of immunomodulation in human glioblastoma.
Tony Avril, Elodie Vauleon, +2 authors, Véronique Quillien.
Immunotherapy, 2011 May 06; 3(4 Suppl). PMID: 21524170
Review.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies.
M J McCoy, R A Lake, +2 authors, A K Nowak.
Br J Cancer, 2012 Aug 23; 107(7). PMID: 22910319    Free PMC article.
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism.
Elizabeth A Manning, John G M Ullman, +6 authors, Leisha A Emens.
Clin Cancer Res, 2007 Jul 04; 13(13). PMID: 17606729
Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation.
Satoko Matsumura, Sandra Demaria.
Radiat Res, 2010 Mar 26; 173(4). PMID: 20334513    Free PMC article.
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.
Mélanie Bruchard, Grégoire Mignot, +12 authors, François Ghiringhelli.
Nat Med, 2012 Dec 04; 19(1). PMID: 23202296
Highly Cited.
Immune defects observed in patients with primary malignant brain tumors.
A R Dix, W H Brooks, T L Roszman, L A Morford.
J Neuroimmunol, 2000 Mar 01; 100(1-2). PMID: 10695732
Review.
Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.
Michelle Hong, Anne-Laure Puaux, +8 authors, Jean-Pierre Abastado.
Cancer Res, 2011 Sep 29; 71(22). PMID: 21948969
Highly Cited.
Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development.
Nhu Nam Tran Thang, Madiha Derouazi, +9 authors, Paul R Walker.
Cancer Res, 2010 May 27; 70(12). PMID: 20501837
Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer.
Jian L Campian, Guneet Sarai, +2 authors, Stuart A Grossman.
Head Neck, 2013 Nov 01; 36(12). PMID: 24174270    Free PMC article.
Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1.
Patrick Roth, Michel Mittelbronn, +3 authors, Michael Weller.
Cancer Res, 2007 Apr 19; 67(8). PMID: 17440061
Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth.
Chien-Sheng Tsai, Fang-Hsin Chen, +7 authors, Ji-Hong Hong.
Int J Radiat Oncol Biol Phys, 2007 Apr 03; 68(2). PMID: 17398016
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.
Surasak Phuphanich, Christopher J Wheeler, +12 authors, John S Yu.
Cancer Immunol Immunother, 2012 Aug 01; 62(1). PMID: 22847020    Free PMC article.
Highly Cited.
Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.
Robert M Prins, Horacio Soto, +5 authors, Linda M Liau.
Clin Cancer Res, 2010 Dec 08; 17(6). PMID: 21135147    Free PMC article.
Highly Cited.
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude, Noelle Frey, +16 authors, Stephan A Grupp.
N Engl J Med, 2014 Oct 16; 371(16). PMID: 25317870    Free PMC article.
Highly Cited.
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
Dung T Le, Eric Lutz, +8 authors, Daniel A Laheru.
J Immunother, 2013 Aug 09; 36(7). PMID: 23924790    Free PMC article.
Highly Cited.
Combination therapy with tumor-lysate pulsed dendritic cells and antiangiogenic drug TNP-470 for mouse pancreatic cancer.
Junichi Miyazaki, Yoshikazu Tsuzuki, +6 authors, Soichiro Miura.
Int J Cancer, 2005 May 21; 117(3). PMID: 15906361
Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics.
Stanleyson V Hato, Andrea Khong, I Jolanda M de Vries, W Joost Lesterhuis.
Clin Cancer Res, 2014 Jun 01; 20(11). PMID: 24879823
Highly Cited. Review.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Eric Tran, Simon Turcotte, +10 authors, Steven A Rosenberg.
Science, 2014 May 09; 344(6184). PMID: 24812403    Free PMC article.
Highly Cited.
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.
W Joost Lesterhuis, Cornelis J A Punt, +11 authors, I Jolanda M de Vries.
J Clin Invest, 2011 Jul 19; 121(8). PMID: 21765211    Free PMC article.
FasL gene knock-down therapy enhances the antiglioma immune response.
Timothy Jansen, Betty Tyler, +5 authors, Alessandro Olivi.
Neuro Oncol, 2010 Apr 22; 12(5). PMID: 20406899    Free PMC article.
Role of microglia in glioma biology.
B Badie, J Schartner.
Microsc Res Tech, 2001 Jul 17; 54(2). PMID: 11455617
Review.
The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma.
Aaron T Wild, Xiaobu Ye, +10 authors, Joseph M Herman.
Am J Clin Oncol, 2013 May 08; 38(3). PMID: 23648440    Free PMC article.
Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.
Lavakumar Karyampudi, Purushottam Lamichhane, +5 authors, Keith L Knutson.
Cancer Res, 2014 Apr 15; 74(11). PMID: 24728077    Free PMC article.
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
Eric A Reits, James W Hodge, +14 authors, Jacques J Neefjes.
J Exp Med, 2006 Apr 26; 203(5). PMID: 16636135    Free PMC article.
Highly Cited.
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells.
Yuting Ma, Sandy Adjemian, +24 authors, Guido Kroemer.
Immunity, 2013 Apr 09; 38(4). PMID: 23562161
Highly Cited.
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
Linda M Liau, Robert M Prins, +8 authors, Michael D Roth.
Clin Cancer Res, 2005 Aug 03; 11(15). PMID: 16061868
Highly Cited.
Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients.
Brendan Fong, Richard Jin, +6 authors, Robert M Prins.
PLoS One, 2012 Apr 10; 7(4). PMID: 22485134    Free PMC article.
Role of Radiation-induced TGF-beta Signaling in Cancer Therapy.
Horatiu C Dancea, Mohammed M Shareef, Mansoor M Ahmed.
Mol Cell Pharmacol, 2009 Jan 01; 1(1). PMID: 20336170    Free PMC article.
An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.
Abdeljabar El Andaloussi, Maciej S Lesniak.
Neuro Oncol, 2006 May 26; 8(3). PMID: 16723631    Free PMC article.
Highly Cited.
Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors.
Derek A Wainwright, Sadhak Sengupta, Yu Han, Maciej S Lesniak.
Neuro Oncol, 2011 Sep 13; 13(12). PMID: 21908444    Free PMC article.
Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation.
Joo-Young Kim, Young-Ok Son, +6 authors, Chi-Dug Kang.
Exp Mol Med, 2006 Nov 03; 38(5). PMID: 17079863
Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro.
M Hishii, T Nitta, +5 authors, K Okumura.
Neurosurgery, 1995 Dec 01; 37(6). PMID: 8584157
The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, +56 authors, TCGA Research Network.
Cell, 2013 Oct 15; 155(2). PMID: 24120142    Free PMC article.
Highly Cited.
Combined antiangiogenic and immune therapy of prostate cancer.
Xiaojun Huang, Tatiana Raskovalova, +5 authors, Elieser Gorelik.
Angiogenesis, 2005 Sep 01; 8(1). PMID: 16132614
Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.
Angelica Facoetti, Rosanna Nano, +5 authors, Soldano Ferrone.
Clin Cancer Res, 2005 Dec 03; 11(23). PMID: 16322289
Chemotherapeutic targeting of cancer-induced immunosuppressive cells.
Darya Alizadeh, Nicolas Larmonier.
Cancer Res, 2014 Apr 30; 74(10). PMID: 24778417    Free PMC article.
Highly Cited. Review.
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.
Joyce E Ohm, Dmitry I Gabrilovich, +4 authors, David P Carbone.
Blood, 2003 Feb 15; 101(12). PMID: 12586633
Highly Cited.
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.
Byron C Burnette, Hua Liang, +5 authors, Sogyong L Auh.
Cancer Res, 2011 Feb 09; 71(7). PMID: 21300764    Free PMC article.
Highly Cited.
Hypoxia potentiates glioma-mediated immunosuppression.
Jun Wei, Adam Wu, +6 authors, Amy B Heimberger.
PLoS One, 2011 Feb 02; 6(1). PMID: 21283755    Free PMC article.
Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway.
Jun Wei, Jason Barr, +10 authors, Amy B Heimberger.
Mol Cancer Ther, 2010 Jan 08; 9(1). PMID: 20053772    Free PMC article.
Highly Cited.
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Stephan A Grupp, Michael Kalos, +10 authors, Carl H June.
N Engl J Med, 2013 Mar 27; 368(16). PMID: 23527958    Free PMC article.
Highly Cited.
ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents.
M R Shurin, H Naiditch, +2 authors, G V Shurin.
Curr Med Chem, 2012 Mar 15; 19(12). PMID: 22414087
Review.
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Derek A Wainwright, Alan L Chang, +9 authors, Maciej S Lesniak.
Clin Cancer Res, 2014 Apr 03; 20(20). PMID: 24691018    Free PMC article.
Highly Cited.
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
John H Sampson, Gary E Archer, +9 authors, Darell D Bigner.
Mol Cancer Ther, 2009 Oct 15; 8(10). PMID: 19825799    Free PMC article.
Highly Cited.
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
John S Yu, Gentao Liu, +3 authors, Christopher J Wheeler.
Cancer Res, 2004 Jul 17; 64(14). PMID: 15256471
Highly Cited.
Prognostic significance and mechanism of Treg infiltration in human brain tumors.
Joannes F M Jacobs, Albert J Idema, +4 authors, Gosse J Adema.
J Neuroimmunol, 2010 Jun 12; 225(1-2). PMID: 20537408
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Consensus guidelines for the detection of immunogenic cell death.
Oliver Kepp, Laura Senovilla, +79 authors, Lorenzo Galluzzi.
Oncoimmunology, 2015 May 06; 3(9). PMID: 25941621    Free PMC article.
Highly Cited. Review.
Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition.
Jason H Fine, Peter Chen, +4 authors, James R Carlyle.
Cancer Res, 2010 Sep 09; 70(18). PMID: 20823164    Free PMC article.
Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
Yuhui Huang, Shom Goel, +2 authors, Rakesh K Jain.
Cancer Res, 2013 Feb 27; 73(10). PMID: 23440426    Free PMC article.
Highly Cited. Review.
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Betty Li, Alshad S Lalani, +7 authors, Karin Jooss.
Clin Cancer Res, 2006 Nov 24; 12(22). PMID: 17121902
A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.
Krithika N Kodumudi, Karrune Woan, +3 authors, Julie Y Djeu.
Clin Cancer Res, 2010 Aug 13; 16(18). PMID: 20702612    Free PMC article.
Highly Cited.
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.
Christiane A Opitz, Ulrike M Litzenburger, +16 authors, Michael Platten.
Nature, 2011 Oct 07; 478(7368). PMID: 21976023
Highly Cited.
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
Rajeev K Shrimali, Zhiya Yu, +3 authors, Steven A Rosenberg.
Cancer Res, 2010 Jul 16; 70(15). PMID: 20631075    Free PMC article.
Highly Cited.
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.
Peter E Fecci, Hidenobu Ochiai, +7 authors, John H Sampson.
Clin Cancer Res, 2007 Apr 04; 13(7). PMID: 17404100
Highly Cited.
Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways.
Victoria Ifeadi, Charlie Garnett-Benson.
PLoS One, 2012 Mar 06; 7(2). PMID: 22389673    Free PMC article.
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
Yuhui Huang, Jianping Yuan, +14 authors, Mark C Poznansky.
Proc Natl Acad Sci U S A, 2012 Oct 10; 109(43). PMID: 23045683    Free PMC article.
Highly Cited.
Dual role of immunomodulation by anticancer chemotherapy.
Michael R Shurin.
Nat Med, 2013 Jan 09; 19(1). PMID: 23296003    Free PMC article.
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.
Mahesh Yadav, Suchit Jhunjhunwala, +11 authors, Lélia Delamarre.
Nature, 2014 Nov 28; 515(7528). PMID: 25428506
Highly Cited.
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.
Amy B Heimberger, Mohamed Abou-Ghazal, +5 authors, Gregory N Fuller.
Clin Cancer Res, 2008 Aug 14; 14(16). PMID: 18698034
Highly Cited.
Rationale for combining immunotherapy with chemotherapy.
Angus G Dalgleish.
Immunotherapy, 2015 Mar 26; 7(3). PMID: 25804482
Review.
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
F Stephen Hodi, Marcus Butler, +17 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2008 Feb 22; 105(8). PMID: 18287062    Free PMC article.
Highly Cited.
The molecular profile of microglia under the influence of glioma.
Wei Li, Manuel B Graeber.
Neuro Oncol, 2012 May 11; 14(8). PMID: 22573310    Free PMC article.
Highly Cited. Review.
Anti-angiogenesis: making the tumor vulnerable to the immune system.
Arjan W Griffioen.
Cancer Immunol Immunother, 2008 Apr 29; 57(10). PMID: 18438662    Free PMC article.
Review.
Immunogenic cell death in cancer therapy.
Guido Kroemer, Lorenzo Galluzzi, Oliver Kepp, Laurence Zitvogel.
Annu Rev Immunol, 2012 Nov 20; 31. PMID: 23157435
Highly Cited. Review.
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
Peter E Fecci, Duane A Mitchell, +7 authors, John H Sampson.
Cancer Res, 2006 Mar 17; 66(6). PMID: 16540683
Highly Cited.
Sustained CD4+ T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide.
Susannah Ellsworth, Ani Balmanoukian, +5 authors, Charles G Drake.
Oncoimmunology, 2014 May 03; 3(1). PMID: 24790790    Free PMC article.
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
Sergio A Quezada, Karl S Peggs, Michael A Curran, James P Allison.
J Clin Invest, 2006 Jun 17; 116(7). PMID: 16778987    Free PMC article.
Highly Cited.
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.
Hilko Ardon, Stefaan W Van Gool, +11 authors, Steven De Vleeschouwer.
Cancer Immunol Immunother, 2012 Apr 25; 61(11). PMID: 22527250
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
John H Sampson, Kenneth D Aldape, +15 authors, Amy B Heimberger.
Neuro Oncol, 2010 Dec 15; 13(3). PMID: 21149254    Free PMC article.
Highly Cited.
Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions.
Michael B Bernstein, Charlie T Garnett, +6 authors, Chandan Guha.
Cancer Biother Radiopharm, 2014 Apr 04; 29(4). PMID: 24693958    Free PMC article.
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
François Ghiringhelli, Nicolas Larmonier, +7 authors, François Martin.
Eur J Immunol, 2004 Feb 10; 34(2). PMID: 14768038
Highly Cited.
Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma.
H B Stone, L J Peters, L Milas.
J Natl Cancer Inst, 1979 Nov 01; 63(5). PMID: 291749
Highly Cited.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.
Simon J Dovedi, Amy L Adlard, +11 authors, Tim M Illidge.
Cancer Res, 2014 Oct 03; 74(19). PMID: 25274032
Highly Cited.
Glioblastoma-derived mechanisms of systemic immunosuppression.
Allen Waziri.
Neurosurg Clin N Am, 2009 Dec 01; 21(1). PMID: 19944964
Review.
Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy.
Yuting Ma, Sandy Adjemian, +2 authors, Guido Kroemer.
Oncoimmunology, 2014 May 07; 3(1). PMID: 24800170    Free PMC article.
Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.
Juan Fu, Ian-James Malm, +3 authors, Young J Kim.
Cancer Res, 2014 May 09; 74(15). PMID: 24812273    Free PMC article.
Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy.
Lei Zhang, Kamtai Dermawan, +7 authors, Sidong Xiong.
Clin Immunol, 2008 Sep 06; 129(2). PMID: 18771959
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Laura Ridolfi, Massimiliano Petrini, +14 authors, Ruggero Ridolfi.
J Transl Med, 2013 Jun 04; 11. PMID: 23725550    Free PMC article.
Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells.
Anita Kumari, Ercan Cacan, Susanna F Greer, Charlie Garnett-Benson.
J Immunother Cancer, 2013 Jan 01; 1. PMID: 24829753    Free PMC article.
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.
Courtney A Crane, Brian J Ahn, Seunggu J Han, Andrew T Parsa.
Neuro Oncol, 2012 Mar 13; 14(5). PMID: 22406925    Free PMC article.
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
John H Sampson, Amy B Heimberger, +13 authors, Darell D Bigner.
J Clin Oncol, 2010 Oct 06; 28(31). PMID: 20921459    Free PMC article.
Highly Cited.
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.
Scott D Brown, Rene L Warren, +4 authors, Robert A Holt.
Genome Res, 2014 May 02; 24(5). PMID: 24782321    Free PMC article.
Highly Cited.
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
Christine Galustian, Brendan Meyer, +10 authors, Angus G Dalgleish.
Cancer Immunol Immunother, 2008 Nov 15; 58(7). PMID: 19009291
Highly Cited.
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Brett E Johnson, Tali Mazor, +31 authors, Joseph F Costello.
Science, 2013 Dec 18; 343(6167). PMID: 24336570    Free PMC article.
Highly Cited.
Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer.
G Schiavoni, F Mattei, +4 authors, E Proietti.
Blood, 2000 Mar 09; 95(6). PMID: 10706870
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.
Benjamin F Johnson, Timothy M Clay, +2 authors, Michael A Morse.
Expert Opin Biol Ther, 2007 Mar 22; 7(4). PMID: 17373897
Review.
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
F Stephen Hodi, Martin C Mihm, +14 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2003 Apr 17; 100(8). PMID: 12682289    Free PMC article.
Highly Cited.
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
Luis A Sanchez-Perez, Bryan D Choi, +9 authors, John H Sampson.
PLoS One, 2013 Mar 26; 8(3). PMID: 23527092    Free PMC article.
Pathway inhibition: emerging molecular targets for treating glioblastoma.
Wolfgang Wick, Michael Weller, +3 authors, Michael Platten.
Neuro Oncol, 2011 Jun 04; 13(6). PMID: 21636705    Free PMC article.
Review.
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Matthew M Gubin, Xiuli Zhang, +24 authors, Robert D Schreiber.
Nature, 2014 Nov 28; 515(7528). PMID: 25428507    Free PMC article.
Highly Cited.
Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.
Darya Alizadeh, Malika Trad, +5 authors, Nicolas Larmonier.
Cancer Res, 2013 Nov 08; 74(1). PMID: 24197130    Free PMC article.
Highly Cited.
Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma.
Peter J Wersäll, Henric Blomgren, +3 authors, Christer Svedman.
Acta Oncol, 2006 Jun 09; 45(4). PMID: 16760190
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.
Jordi Rodon, Michael A Carducci, +15 authors, Jose Baselga.
Clin Cancer Res, 2014 Nov 27; 21(3). PMID: 25424852    Free PMC article.
Highly Cited.
Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber.
Science, 2015 Apr 04; 348(6230). PMID: 25838375
Highly Cited. Review.
VEGF as a mediator of tumor-associated immunodeficiency.
J E Ohm, D P Carbone.
Immunol Res, 2001 Jul 11; 23(2-3). PMID: 11444391
Review.
T-cell apoptosis in human glioblastoma multiforme: implications for immunotherapy.
David G Walker, Teong Chuah, Michael J Rist, Michael P Pender.
J Neuroimmunol, 2006 Apr 25; 175(1-2). PMID: 16631933
HLA-binding properties of tumor neoepitopes in humans.
Edward F Fritsch, Mohini Rajasagi, +3 authors, Catherine J Wu.
Cancer Immunol Res, 2014 Jun 05; 2(6). PMID: 24894089    Free PMC article.
Highly Cited. Review.
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.
D I Gabrilovich, H L Chen, +5 authors, D P Carbone.
Nat Med, 1996 Oct 01; 2(10). PMID: 8837607
Highly Cited.
Combining radiotherapy and cancer immunotherapy: a paradigm shift.
Silvia C Formenti, Sandra Demaria.
J Natl Cancer Inst, 2013 Jan 08; 105(4). PMID: 23291374    Free PMC article.
Highly Cited. Review.
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.
Camilo E Fadul, Jan L Fisher, +9 authors, Marc S Ernstoff.
J Immunother, 2011 Apr 19; 34(4). PMID: 21499132    Free PMC article.
Immunotherapy for primary brain tumors: no longer a matter of privilege.
Peter E Fecci, Amy B Heimberger, John H Sampson.
Clin Cancer Res, 2014 Nov 16; 20(22). PMID: 25398845    Free PMC article.
Review.
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.
S Farzana Hussain, David Yang, +3 authors, Amy B Heimberger.
Neuro Oncol, 2006 Jun 16; 8(3). PMID: 16775224    Free PMC article.
Highly Cited.
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?
Chad Tang, Xiaohong Wang, +14 authors, James W Welsh.
Cancer Immunol Res, 2014 Sep 05; 2(9). PMID: 25187273    Free PMC article.
Highly Cited. Review.
Adhesion molecules in radiotherapy.
Roxana G Baluna, Tony Y Eng, Charles R Thomas.
Radiat Res, 2006 Dec 08; 166(6). PMID: 17149971
Review.
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, +11 authors, IMPACT Study Investigators.
N Engl J Med, 2010 Sep 08; 363(5). PMID: 20818862
Highly Cited.
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.
M E Christine Lutsiak, Roshanak T Semnani, +3 authors, Helen Sabzevari.
Blood, 2004 Dec 14; 105(7). PMID: 15591121
Highly Cited.
CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model.
Cheol-Hun Son, Jae-Ho Bae, +7 authors, You-Soo Park.
J Immunother, 2013 Dec 10; 37(1). PMID: 24316550
Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions.
Jennifer K Mulligan, Terry A Day, +2 authors, M Rita I Young.
Hum Immunol, 2009 Jun 02; 70(6). PMID: 19480853    Free PMC article.
Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein.
Courtney A Crane, Seunggu J Han, +10 authors, Andrew T Parsa.
Clin Cancer Res, 2012 Aug 09; 19(1). PMID: 22872572
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
Jing Zeng, Alfred P See, +18 authors, Michael Lim.
Int J Radiat Oncol Biol Phys, 2013 Mar 07; 86(2). PMID: 23462419    Free PMC article.
Highly Cited.
Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.
Dieter Lemke, Philipp-Niclas Pfenning, +8 authors, Wolfgang Wick.
Clin Cancer Res, 2011 Nov 15; 18(1). PMID: 22080438
Radiation enhances regulatory T cell representation.
Evelyn L Kachikwu, Keisuke S Iwamoto, +5 authors, Dörthe Schaue.
Int J Radiat Oncol Biol Phys, 2010 Nov 26; 81(4). PMID: 21093169    Free PMC article.
Impaired capacity for upregulation of MHC class II in tumor-associated microglia.
Jill M Schartner, Aaron R Hagar, +3 authors, Behnam Badie.
Glia, 2005 Apr 09; 51(4). PMID: 15818597
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
Eric Tartour, H Pere, +11 authors, S Oudard.
Cancer Metastasis Rev, 2011 Jan 21; 30(1). PMID: 21249423
Highly Cited. Review.
Bevacizumab plus ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Donald Lawrence, +20 authors, David McDermott.
Cancer Immunol Res, 2014 May 20; 2(7). PMID: 24838938    Free PMC article.
Highly Cited.
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Claire Banissi, François Ghiringhelli, Lin Chen, Antoine F Carpentier.
Cancer Immunol Immunother, 2009 Feb 18; 58(10). PMID: 19221744
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Exploiting the mutanome for tumor vaccination.
John C Castle, Sebastian Kreiter, +13 authors, Ugur Sahin.
Cancer Res, 2012 Jan 13; 72(5). PMID: 22237626
Highly Cited.
Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
Chang-Hyun Kim, Sun-Je Woo, +5 authors, Tai-Gyu Kim.
Immunology, 2007 Jul 25; 122(4). PMID: 17645496    Free PMC article.
CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.
Yuting Ma, Stephen R Mattarollo, +15 authors, Guido Kroemer.
Cancer Res, 2013 Dec 05; 74(2). PMID: 24302580
Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.
D Gabrilovich, T Ishida, +4 authors, D P Carbone.
Blood, 1998 Dec 03; 92(11). PMID: 9834220
Highly Cited.
Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.
Thomas Urup, Signe Regner Michaelsen, +9 authors, Ulrik Lassen.
Mol Oncol, 2016 Jun 06; 10(8). PMID: 27262894    Free PMC article.
REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells.
Anantha L Marisetty, Sanjay K Singh, +3 authors, Sadhan Majumder.
Neuro Oncol, 2017 Jan 04; 19(4). PMID: 28040710    Free PMC article.
The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
David A Reardon, Duane A Mitchell.
Semin Immunopathol, 2017 Feb 01; 39(2). PMID: 28138787
Review.
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
Lijie Zhai, Erik Ladomersky, +8 authors, Derek A Wainwright.
Brain Behav Immun, 2017 Feb 10; 62. PMID: 28179106    Free PMC article.
Reconfigurable Microfluidic Magnetic Valve Arrays: Towards a Radiotherapy-Compatible Spheroid Culture Platform for the Combinatorial Screening of Cancer Therapies.
Alexandre R Brunet, Frédérique Labelle, Philip Wong, Thomas Gervais.
Sensors (Basel), 2017 Oct 05; 17(10). PMID: 28976942    Free PMC article.
Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Chia-Ing Jan, Wan-Chen Tsai, +5 authors, Der-Yang Cho.
Front Immunol, 2018 Jun 19; 9. PMID: 29910795    Free PMC article.
Combination therapy to checkmate Glioblastoma: clinical challenges and advances.
Debarati Ghosh, Saikat Nandi, Sonali Bhattacharjee.
Clin Transl Med, 2018 Oct 18; 7(1). PMID: 30327965    Free PMC article.
Highly Cited. Review.
Efficacy of ruthenium coordination complex-based Rutherrin in a preclinical rat glioblastoma model.
Manjunatha Akathatti Munegowda, Carl Fisher, +6 authors, Lothar Lilge.
Neurooncol Adv, 2019 May 28; 1(1). PMID: 32642649    Free PMC article.
OncoPDSS: an evidence-based clinical decision support system for oncology pharmacotherapy at the individual level.
Quan Xu, Jin-Cheng Zhai, +13 authors, Zhi Zhang.
BMC Cancer, 2020 Aug 11; 20(1). PMID: 32770988    Free PMC article.